Login to Your Account



Emerging Markets

Compulsory Licensing: Much Ado or a Game-Changer?

By Michael Harris
Senior Editor

Monday, June 18, 2012
The cost of doing biopharma business in Brazil, Russia, India and China, as well as other emerging and underdeveloped markets, could come with a significant trade-off if the budding compulsory licensing trend gains traction. And, at the moment, there's not much brand makers can do about it.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription